The financials
Precigen, Inc. by the numbers
Precigen, Inc. (PGEN) reported revenue of $23M in Q1 2026 (quarter ended Mar 31, 2026), up 1634% from the same quarter a year earlier. That came with net loss of $7.9M. For the full year FY2025, revenue was $9.7M (+147% year on year) and net income −$251M. Its largest product in Jun 2026 was Papzimeos at $53M, 97% of the disclosed total, well ahead of Service at 3.1%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $23M | $1.3M | +1634% |
| Operating income | −$6.0M | −$23M | n/a |
| Net income | −$7.9M | −$54M | n/a |
| Diluted EPS | −$0.02 | −$0.18 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Papzimeos | $53M | 97% |
| Service | $1.7M | 3.1% |
| Exemplar | $192K | 0.3% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $55.0M (+136%)
Exemplar grew +368% year on yearService +111% year on year
Segment Latestquarter on quarteryear on year
- Papzimeos$53.1M$53.1MQoQ +146%year on year -+146%-
- Service$1.7M$1.7MQoQ +21%year on year +111%+21%+111%
- Exemplar$192.0K$192.0KQoQ -19%year on year +368%-19%+368%